Osmol Therapeutics Announces Closing Of Series A-1 Funding To Advance The Clinical Development Of The First Therapy To Prevent Chemotherapy-Induced Neuropathy
Osmol Therapeutics Announces Closing Of Series A-1 Funding To Advance The Clinical Development Of The First Therapy To Prevent Chemotherapy-Induced Neuropathy
04/12/22, 11:00 AM
Location
new havenIndustry
financial services
health care
Round Type
series a
Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN), today announced that it has closed the first $5.2 million tranche of a $7.5 million Series A-1 financing led by Koax Investment Partners, a fund formed by the founders of Biohaven Pharmaceuticals. Osmol’s lead drug candidate, OSM-0205, is based on Dr. Barbara Ehrlich’s research in neuronal calcium sensor-1 (NCS1) and was in-licensed from Yale University. OSM-0205 is designed to prevent the off-target calcium surge caused by taxanes and potentially other chemotherapy treatments associated with peripheral nerve damage.
Company Info
Location
new haven, kentucky, united states
Additional Info
Osmol Therapeutics is a privately held biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN) based on the ground-breaking work of Dr. Barbara Ehrlich. The company’s lead indication will be for the prevention of CIPN related to taxane treatment. As an example of the extent of this condition, up to 80% of taxane-treated patients with breast cancer have been reported to experience CIPN. For more information, please go to https://osmoltherapeutics.com/.